Tedisamil

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Tedisamil
Accession Number
DB06200
Type
Small Molecule
Groups
Investigational
Description

Tedisamil (planned trade name Pulzium) is an investigational drug for atrial fibrillation and atrial flutter. It is currently being developed by Solvay and is currently under regulatory review by the United States Food and Drug Administration.

Structure
Thumb
Synonyms
Not Available
External IDs
KC-8857 / KC8857
International/Other Brands
Pulzium
Categories
UNII
A5VAY2U3R8
CAS number
90961-53-8
Weight
Average: 288.4708
Monoisotopic: 288.256549034
Chemical Formula
C19H32N2
InChI Key
CTIRHWCPXYGDGF-UHFFFAOYSA-N
InChI
InChI=1S/C19H32N2/c1-2-8-19(7-1)17-11-20(9-15-3-4-15)12-18(19)14-21(13-17)10-16-5-6-16/h15-18H,1-14H2
IUPAC Name
3,7-bis(cyclopropylmethyl)-3,7-diazaspiro[bicyclo[3.3.1]nonane-9,1'-cyclopentane]
SMILES
C(C1CC1)N1CC2CN(CC3CC3)CC(C1)C21CCCC1

Pharmacology

Indication

Investigated for use/treatment in arrhythmia, atrial fibrillation, and angina.

Pharmacodynamics
Not Available
Mechanism of action

It is hypothesized tedisamil prevents Ca2+ overload by the cAMP dependent SR Ca2+ uptake [PMID: 10707827].

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbexinostatThe risk or severity of QTc prolongation can be increased when Tedisamil is combined with Abexinostat.
AcebutololThe risk or severity of QTc prolongation can be increased when Acebutolol is combined with Tedisamil.
AceprometazineThe risk or severity of QTc prolongation can be increased when Aceprometazine is combined with Tedisamil.
AcetyldigoxinThe risk or severity of QTc prolongation can be increased when Acetyldigoxin is combined with Tedisamil.
AcrivastineThe risk or severity of QTc prolongation can be increased when Acrivastine is combined with Tedisamil.
AdenosineThe risk or severity of QTc prolongation can be increased when Adenosine is combined with Tedisamil.
AjmalineThe risk or severity of QTc prolongation can be increased when Ajmaline is combined with Tedisamil.
AlfuzosinThe risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Tedisamil.
AlimemazineThe risk or severity of QTc prolongation can be increased when Alimemazine is combined with Tedisamil.
AmantadineThe risk or severity of QTc prolongation can be increased when Amantadine is combined with Tedisamil.
Food Interactions
Not Available

References

General References
  1. Manoach M, Varon D, Tribulova N, Zinman T, Kaplan D, Khananshvili D, Shainberg A: The role of sarcoplasmic reticulum in the protective effect of class III drugs against Ca2+ overload. Gen Physiol Biophys. 1999 Dec;18 Suppl 1:19-25. [PubMed:10707827]
External Links
PubChem Compound
65825
ChemSpider
59237
BindingDB
50088367
ChEMBL
CHEMBL113461
Wikipedia
Tedisamil
ATC Codes
C01BD06 — Tedisamil

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0214 mg/mLALOGPS
logP3.54ALOGPS
logP2.78ChemAxon
logS-4.1ALOGPS
pKa (Strongest Basic)9.56ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area6.48 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity88.51 m3·mol-1ChemAxon
Polarizability35.69 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9531
Blood Brain Barrier+0.9902
Caco-2 permeable+0.5654
P-glycoprotein substrateSubstrate0.5855
P-glycoprotein inhibitor IInhibitor0.5632
P-glycoprotein inhibitor IIInhibitor0.7142
Renal organic cation transporterInhibitor0.6926
CYP450 2C9 substrateNon-substrate0.8756
CYP450 2D6 substrateNon-substrate0.5146
CYP450 3A4 substrateNon-substrate0.6512
CYP450 1A2 substrateNon-inhibitor0.9246
CYP450 2C9 inhibitorNon-inhibitor0.9269
CYP450 2D6 inhibitorNon-inhibitor0.7712
CYP450 2C19 inhibitorNon-inhibitor0.8482
CYP450 3A4 inhibitorInhibitor0.5997
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6721
Ames testNon AMES toxic0.5268
CarcinogenicityNon-carcinogens0.9445
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7945 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.781
hERG inhibition (predictor II)Inhibitor0.5367
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as azaspirodecane derivatives. These are organic compounds containing a spirodecane moiety with at least one nitrogen atom.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azaspirodecane derivatives
Sub Class
Not Available
Direct Parent
Azaspirodecane derivatives
Alternative Parents
Piperidines / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Azaspirodecane / Piperidine / Tertiary aliphatic amine / Tertiary amine / Azacycle / Organic nitrogen compound / Organopnictogen compound / Hydrocarbon derivative / Organonitrogen compound / Amine
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on March 19, 2008 10:17 / Updated on November 02, 2018 06:14